Retrospective observational cohort study on innovation in oncology and progress in survival: how far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a single population?

Justo, Nahila, Nilsson, Jonas, Korytowsky, Beata, Dalen, Johan, Madison, Terri and McGuire, Alistair ORCID: 0000-0002-5367-9841 (2020) Retrospective observational cohort study on innovation in oncology and progress in survival: how far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a single population? PLOS ONE, 15 (5). ISSN 1932-6203

Text (Retrospective observational cohort study on innovation in oncology and progress in survival) - Published Version Available under License Creative Commons Attribution. Download (1MB)

• Scopus publication
• Author

Abstract

We assessed the impact of new antineoplastic agents on the overall survival (OS) of advanced non-small cell lung cancer (aNSCLC) patients followed up until 2012. Multivariate regression models were run for OS (outcome) and four proxies for innovation (exposure): Index (InnovInd, for SEER-Research data 1973–2012) and three levels of aggregation of Mean Medication Vintage, i.e. Overall (MMVOverall), using data aggregated at the State Level (MMVState), and using patient-level data (MMVPatient) using data from the US captured in SEER-Medicare 1991–2012. We derived Hazard ratios (HR) from Royston-Parmar models and odds ratios (OR) from a logistic regression on 1-year OS. Including 164,704 patients (median age 72 years, 56.8% stage IV, 61.8% with no comorbidities, 37.8% with adenocarcinoma, 22.9% with squamous-cell, 6.1% were censored). One-year OS improved from 0.22 in 1973 to 0.39 in 2012, in correlation with InnovInd (r = 0.97). Ten new NSCLC drugs were approved and 28 more used off-label. Regression-models results indicate that therapeutic innovation only marginally reduced the risk of dying (HROverall = 0.98 [0.98–0.98], HRMMV-Patient = 0.98 [0.97–0.98], and HRMMV-State = 0.98 [0.98–0.98], and slightly improved 1-year survival (ORMMV-Overall = 1.05 95%CI [1.04–1.05]). These results were validated with data from the Swedish National Health Data registers. Until 2013, aNSCLC patients were treated undifferentiated and the introduction of innovative therapies had statistically significant, albeit modest, effects on survival. Most treatments used off-guidelines highlight the high unmet need; however new advancements in treatment may further improve survival.

Item Type:	Article
Official URL:	https://journals.plos.org/plosone/
Additional Information:	© 2020 The Authors
Divisions:	Health Policy
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Date Deposited:	27 May 2020 10:24
Last Modified:	01 Nov 2024 05:34
URI:	http://eprints.lse.ac.uk/id/eprint/104599

Actions (login required)

View Item